Opinion|Videos|January 17, 2025
CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel
Panelists discuss how patient selection criteria and individual characteristics help determine whether ide-cel or cilta-cel is the more appropriate chimeric antigen receptor T-cell therapy choice for early-line treatment in patients with multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Which patients do you think about for chimeric antigen receptor T-cell therapy (CAR T) in second-line treatment for relapsed/refractory multiple myeloma (cilta-cel vs ide-cel)?
- Dr Usmani to ask Dr Mailankody: Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T referral?
- How do nonmedical factors (location, money, etc) impact patient selection?
Advertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
4
Tile-Based Radiation Improves Surgical Bed Recurrence in Brain Metastases
5